A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine
The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).
Breast Cancer|Pregnancy
DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Ado-Trastuzumab Emtansine
Number of Participants Developing Oligohydramnios, From enrollment up to the delivery or upon termination of pregnancy (up to 12 months)|Number of Live Births, From Week 20 of gestation to the delivery or upon termination of pregnancy (up to 12 months)|Number of Fetal Deaths/Stillbirths, From Week 20 of gestation to the delivery or upon termination of pregnancy (up to 12 months)|Number of Fetal or Infant Major Malformations, From delivery up to 12 months after delivery|Number of Fetal or Infant Deformations, From delivery up to 12 months after delivery|Number of Fetal or Infant Disruptions, From delivery up to 12 months after delivery|Number of Fetal or Infant Functional Deficits, From delivery up to 12 months after delivery
Number of Spontaneous Abortions, From enrollment up to 12 months|Number of Therapeutic Abortions, or Elective Abortions, From enrollment up to 12 months|Number of Premature Births, From enrollment up to 12 months|Number of Infants Small for Gestational Age, From delivery up to 12 months after delivery|Number of Cases of Intrauterine Growth Restriction (IUGR), From enrollment up to 12 months|Number of Other Specific Pregnancy or Delivery Complications, From enrollment up to 12 months
The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).